You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning ( ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning (ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are u ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAR-21-226: Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)

    Release Date: 04-30-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 09-06-2024

    Many NIH-funded research projects rely on vertebrate and invertebrate animal models to study the basics of biology and physiology, to investigate pathological conditions, to examine disease mechanisms and treatments, and to design novel therapies and translational procedures. In this regard, ORIP plays a vital role through its support of research infrastructures and animal models of human diseases ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-21-225: Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)

    Release Date: 04-30-2021Open Date: 08-06-2021 Due Dates: Multiple Close Date: 09-06-2024

    Many NIH-funded research projects rely on vertebrate and invertebrate animal models to study the basics of biology and physiology, to investigate pathological conditions, to examine disease mechanisms and treatments, and to design novel therapies and translational procedures. In this regard, the Office of Research Infrastructure Programs (ORIP) plays a vital role through its support of research in ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-21-225: Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)

    Release Date: 04-30-2021Open Date: 08-06-2021 Due Dates: Multiple Close Date: 09-06-2024

    Many NIH-funded research projects rely on vertebrate and invertebrate animal models to study the basics of biology and physiology, to investigate pathological conditions, to examine disease mechanisms and treatments, and to design novel therapies and translational procedures. In this regard, the Office of Research Infrastructure Programs (ORIP) plays a vital role through its support of research in ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. A244-P017: xTechScalable AI 2

    Release Date: 10-03-2023Open Date: 03-11-2024Due Date: 03-31-2025Close Date: 11-18-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Artificial Intelligence/ Machine Learning; Trusted AI and Autonomy; Advanced Computing and Software; Human-Machine Interfaces OBJECTIVE: Topic 1: Scalable Tools for Automated AI Risk Management and Algorithmic Analysis As the Army deploys Artificial Intelligence (AI) systems, there is an inherent risk that the AI model could fail to perform as expe ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  8. PAR-22-102: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-22-103: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44- Clinical Trial Optional)

    Release Date: 03-28-2022Open Date: 07-15-2022 Due Dates: Multiple Close Date: 02-15-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government